Singapore markets close in 7 minutes
Straits Times Index
3,269.66 +44.49 (+1.38%) Nikkei
37,552.16 +113.55 (+0.30%) Hang Seng
16,828.93 +317.24 (+1.92%) FTSE 100
8,041.34 +17.47 (+0.22%) Bitcoin USD
66,182.65 +114.32 (+0.17%) CMC Crypto 200
1,393.13 -21.63 (-1.53%)
ABBV Jan 2025 105.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:03PM EDT. Market open.
| Previous close | 0.9000 |
| Open | 0.9000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 105.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.9000 - 0.9000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksAbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
Investor focus is likely to be on the sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports first-quarter results.
ZacksEarnings Preview: AbbVie (ABBV) Q1 Earnings Expected to Decline
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksPharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data
J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.
© 2024 Yahoo. All rights reserved.